Claim

1. A use of a polypeptide for preparation of a medicament for treating and/or limiting fibrotic disorders in an individual in need thereof, the polypeptide comprising the sequence WLRRASAPLPGLK (SEQ ID NO:300), wherein the S residue is phosphorylated;

wherein the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281); and

the individual in need thereof is a highly pigmented individual.

2. A use of a polypeptide for preparation of a medicament for treating and/or limiting scars selected from the group consisting of keloids and hypertrophic scars in an individual in need thereof the polypeptide comprising the sequence WLRRASAPLPGLK (SEQ ID NO: 300), wherein the S residue is phosphorylated;

wherein the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281); and

the individual in need thereof is a highly pigmented individual.

3. The use of claim 2 to treat or limit scars selected from the group consisting of keloids and hypertrophic scars, and wherein the individual in need thereof is of Asian or African descent.

4. The use of claim 1 or 2, wherein the use is used to treat or limit fibrotic disorders, and wherein the individual in need thereof is suffering from or at risk of one or more of diabetic nephropathy, glomerulosclerosis, IgA nephropathy, diabetic retinopathy, macular degeneration, cirrhosis, biliary atresia, congestive heart failure, scleroderma, and abdominal adhesions.

5. The use of claim 1 to treat or limit fibrotic disorders wherein the individual in need thereof is of Asian or African descent.

6. The method of any of claims 1-5, wherein the polypeptide comprises YARAAARQARAWLRRApSAPLPGLK (SEQ ID NO: 315) wherein pS represents a phosphorylated serine residue.

Claim

1. A use of a polypeptide for preparation of a medicament for treating and/or limiting fibrotic disorders in a highly pigmented individual in need thereof, the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281);

wherein the polypeptide on the C-terminal side comprising the sequence WLRRASAPLPGLK (SEQ ID NO: 300); wherein the S residue is phosphorlylated.

2. A use of a polypeptide for preparation of a medicament for treating and/or limiting scars selected from the group consisting of keloids and hypertrophic scars in an individual in need thereof the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281); and

the individual in need thereof is a highly pigmented individual;

wherein the polypeptide on the C-terminal side comprising the sequence WLRRASAPLPGLK (SEQ ID NO: 300), wherein the S residue is phosphorylated.

3. The use of claim 2 wherein the medicament is used to treat or limit scars selected from the group consisting of keloids and hypertrophic scars, and wherein the individual in need thereof is of Asian or African descent.

4. The use of claim 1 or 2, wherein the medicament is used to treat or limit one or more fibrotic disorders selected from the group consisting of, diabetic nephropathy, glomerulosclerosis, IgA nephropathy, diabetic retinopathy, macular degeneration, cirrhosis, biliary atresia, congestive heart failure, scleroderma, and abdominal adhesions.

5. The use of claim 1 to treat or limit fibrotic disorders wherein the individual in need thereof is of Asian or African descent.

6. The use of any of claims 1-5, wherein the polypeptide is YARAAARQARAWLRRApSAPLPGLK (SEQ ID NO: 315) wherein pS represents a phosphorlylated serine residue.

7. A pharmaceutical composition for treating and/or limiting fibrotic disorders in a highly pigmented individual in need thereof, the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281);

wherein the polypeptide on the C-terminal side comprising the sequence WLRRASAPLPGLK (SEQ ID NO: 300), wherein the S residue is phosphorlylated.

8. A pharmaceutical composition for treating and/or limiting scars selected from the group consisting of keloids and hypertrophic scars in an individual in need thereof the polypeptide further comprises a covalently bound transduction domain comprising the sequence YARAAARQARA (SEQ ID NO: 281);

wherein the polypeptide on the C-terminal side comprising the sequence WLRRASAPLPGLK (SEQ ID NO: 300), wherein the S residue is phosphorylated; and

the individual in need thereof is a highly pigmented individual.

9. The pharmaceutical composition of claim 8, wherein the composition is used to treat or limit scars selected from the group consisting of keloids and hypertrophic scars, and wherein the individual in need thereof is of Asian or African descent.

10. The pharmaceutical composition of claim 7 or 8, wherein the composition is used to treat or limit one or more fibrotic disorders selected from the group consisting of diabetic nephropathy, glomerulosclerosis, IgA nephropathy, diabetic retinopathy, macular degeneration, cirrhosis, biliary atresia, congestive heart failure, scleroderma, and abdominal adhesions.

11. The pharmaceutical composition of claim 7 to treat or limit fibrotic disorders wherein the individual in need thereof is of Asian or African descent.

12. The pharmaceutical composition of any of claims 7-11, wherein the polypeptide is YARAAARQARAWLRRApSAPLPGLK (SEQ ID NO: 315) wherein pS represents a phosphorlylated serine residue.